Free Trial

Rocket Pharmaceuticals (RCKT) Competitors

Rocket Pharmaceuticals logo
$4.04 +0.33 (+8.76%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RCKT vs. PAHC, SDGR, HROW, SNDX, EVO, ZYME, AVDL, TSHA, ORIC, and SION

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Phibro Animal Health (PAHC), Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Zymeworks (ZYME), Avadel Pharmaceuticals (AVDL), Taysha Gene Therapies (TSHA), Oric Pharmaceuticals (ORIC), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.

Rocket Pharmaceuticals vs. Its Competitors

Phibro Animal Health (NASDAQ:PAHC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Phibro Animal Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$1.30B1.26$48.26M$1.1834.28
Rocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.61

Phibro Animal Health has a net margin of 3.73% compared to Rocket Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 32.14% beat Rocket Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health3.73% 32.14% 6.89%
Rocket Pharmaceuticals N/A -65.11%-55.99%

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Phibro Animal Health currently has a consensus target price of $28.40, indicating a potential downside of 29.79%. Rocket Pharmaceuticals has a consensus target price of $16.67, indicating a potential upside of 313.05%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.13
Rocket Pharmaceuticals
2 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33

Phibro Animal Health has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for Rocket Pharmaceuticals and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.32 beat Rocket Pharmaceuticals' score of 0.26 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phibro Animal Health
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rocket Pharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Phibro Animal Health beats Rocket Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKT vs. The Competition

MetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$434.30M$3.46B$6.16B$10.68B
Dividend YieldN/A2.27%5.72%4.83%
P/E Ratio-1.6023.2629.4127.39
Price / SalesN/A477.36587.23132.67
Price / CashN/A45.2825.8230.35
Price / Book0.7910.5512.456.68
Net Income-$258.75M-$52.62M$3.32B$276.36M
7 Day Performance16.28%4.79%2.22%0.85%
1 Month Performance31.43%15.84%8.56%3.81%
1 Year Performance-78.56%14.06%61.78%36.40%

Rocket Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCKT
Rocket Pharmaceuticals
4.8674 of 5 stars
$4.04
+8.8%
$16.67
+313.1%
-80.3%$434.30MN/A-1.60240Analyst Revision
Gap Up
PAHC
Phibro Animal Health
3.7043 of 5 stars
$36.58
+0.5%
$28.40
-22.4%
+65.0%$1.48B$1.30B31.002,475
SDGR
Schrodinger
3.5565 of 5 stars
$19.70
+3.2%
$26.29
+33.4%
+8.5%$1.40B$207.54M-7.94790Gap Up
HROW
Harrow
2.9951 of 5 stars
$38.77
+3.4%
$68.50
+76.7%
-30.4%$1.39B$199.61M-155.08180
SNDX
Syndax Pharmaceuticals
4.0458 of 5 stars
$15.20
-5.4%
$39.22
+158.0%
-27.4%$1.38B$23.68M-3.91110News Coverage
Analyst Revision
EVO
Evotec
1.7147 of 5 stars
$3.95
+2.1%
$7.00
+77.2%
+20.5%$1.37B$862.40M0.004,827
ZYME
Zymeworks
2.9495 of 5 stars
$18.11
+0.3%
$22.50
+24.2%
+36.5%$1.36B$122.87M-12.07460
AVDL
Avadel Pharmaceuticals
2.6358 of 5 stars
$14.20
+1.4%
$20.86
+46.9%
+12.2%$1.36B$169.12M-473.3370
TSHA
Taysha Gene Therapies
2.7197 of 5 stars
$5.05
+3.5%
$9.00
+78.2%
+129.1%$1.33B$8.33M-14.85180Analyst Forecast
ORIC
Oric Pharmaceuticals
4.345 of 5 stars
$13.91
+1.7%
$17.29
+24.3%
+35.2%$1.33BN/A-7.3680Positive News
SION
Sionna Therapeutics
2.3736 of 5 stars
$29.31
-0.4%
$38.00
+29.6%
N/A$1.30BN/A0.0035Insider Trade

Related Companies and Tools


This page (NASDAQ:RCKT) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners